Surmodics tops Q4 sales estimates, misses on EPS

Shares in Surmodics (NSDQ:SRDX) fell today after the medical device maker topped sales expectations but missed EPS estimates on Wall Street with its fourth-quarter financial results.

The Eden Prairie, Minn.-based company was in the red this quarter, posting a net loss of -$1.8 million, or -13¢ per share, on sales of $23 million for the three months ended Sept. 30. Sales were up 15% compared to the same period last year.

Adjusted to exclude 1-time items, EPS were -5¢, just 2¢ behind consensus on The Street. The company beat revenue expectations, though – analysts were looking for sales of $21.6 million.

“We continue to drive strong revenue growth and solid operational performance as we execute on our strategic objectives,” president & CEO Gary Maharaj said in prepared remarks. “The positive twelve-month data recently presented from Preveil, the early feasibility study of our SurVeil DCB and the recent submission for first in-human study for our AV access DCB, AVess, demonstrate meaningful progress towards our whole-products solutions initiatives.”

Surmodics said it expects to post sales of $92 million to $97 million for the full fiscal year of 2019.

SRDX shares were trading at $64.00 apiece today in morning activity, down -3.9%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW